Navigation Links
ChanTest CEO named Distinguished Service Award recipient by the Safety Pharmacology Society
Date:7/24/2013

CLEVELAND, July 24, 2013 /PRNewswire/ -- ChanTest proudly announces that CEO, President and Founder, Arthur "Buzz" Brown, M.D., Ph.D. has been named the recipient of the prestigious Distinguished Service Award by the Safety Pharmacology Society (SPS).  The following statement was issued by the SPS, "The award is in recognition of Dr. Brown's significant scientific contributions to many areas of Safety Pharmacology, most notably contributions to ion channels and their relationship to human disease."

(Photo: http://photos.prnewswire.com/prnh/20130724/CL50851 )

The SPS will officially present the award at the 13th SPS Annual Meeting in Rotterdam, The Netherlands.  As part of the ceremony, Dr. Brown will present a talk entitled, "Predicting Cardiac Safety: From Molecules to Man" on Thursday, September 19, 2013 from 11:30–12:00 at the Congress Centre de Doelen in Rotterdam.

Dr. Brown's establishment of ChanTest in 1998 allowed pharma and biotech companies to outsource important and unique safety pharmacology studies that have proven difficult and costly to implement "in-house".  To this date, Dr. Brown's lab team at ChanTest continues to provide cutting edge assays that serve the Safety Pharmacology industry.

Dr. Brown collaborates with the US Federal Drug Administration (FDA) on cardiac safety issues and he holds nine patents on ion channel pharmacology, therapeutics and devices.

"I am honored to receive this award," said Dr. Brown.  "The Safety Pharmacology Society has played a key role in the making of better and safer medicines by the pharmaceutical industry." 

For more details about Dr. Brown's career, click here.

About ChanTest – The Ion Channel Expert
ChanTest's mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the company has tested compounds for more than 300 global pharmaceutical and biotechnology companies and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company's library of validated ion channel cell lines and pre-clinical cardiac risk assessment service portfolio are the most comprehensive commercially available today. Because of ChanTest's seminal role in the nonclinical cardiac safety field, along with the company's uncompromising commitment to quality, ChanTest has been named the "most trusted and most used fee-for-service provider" for ion channel screening in independent surveys since 2006. ChanTest is based in Cleveland, Ohio. For more information, e-mail info@chantest.com.

 


'/>"/>
SOURCE ChanTest Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ChanTest Awarded $1 Million Grant for Predictive Assays using Stem Cell-Derived Human Cardiomyocytes
2. ChanTest hires Chris Mathes as Chief Commercial Officer
3. Roger Graham Named President of Mylan Specialty
4. Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings
5. Philips Named 2013 Overall Performance Leader In Imaging Equipment By KLAS
6. Baby Eva Named After Pioneering IVF Test
7. Comprehensive Care Corporation CEO Clark A. Marcus Named to Board of Americas Agenda: Health Care for All
8. Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
9. Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year
10. RenovoRx Named Winner of 2013 TiE50 "Top Startup"
11. Wyle Aided System Gets Named to Space Technology Hall of Fame
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 1, 2016  Today, Simpson Healthcare Executives, ... honor of being selected as winners of multiple awards ... Executives Website at the PLATINUM level, Blue Zones Menu ... at the GOLD Level, and our proprietary 3ConneX Platform ... Simpson Healthcare Executives, we are excited to showcase our ...
(Date:12/2/2016)... BRUSSELS , Dec. 2, 2016  UCB is pleased to ... presentation at the upcoming 70 th American Epilepsy Society ... Houston, TX , USA. 1-12 ... safety and efficacy profile of VIMPAT ® (lacosamide) CV ... also share findings on the current state of the union ...
(Date:12/2/2016)... Dec. 2, 2016 Allergan plc (NYSE: ... information on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a ... the Company will repurchase $10 billion of its ordinary shares. ...
Breaking Medicine Technology:
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 02, 2016 , ... ... the Open Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare ... plan (Part C) or prescription drug plan (Part D) need to make changes during ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... inspirational interview of two ostomy patients, standing as living proof that attitude and ... from digestive diseases and issues that spike around the holidays. This campaign will ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic technologies, ... while maintaining fulfilling lives. “We are prolonging life 6 years in the last ...
(Date:12/2/2016)... OH (PRWEB) , ... December 02, 2016 , ... ... of veterinarian diagnostic imaging systems and the first company to offer ... With a Heart at their tradeshow booth # 941 for the American Association ...
(Date:12/2/2016)... ... 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, ... into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in ... the details line up exactly with Bible Prophecy – a protected way for those ...
Breaking Medicine News(10 mins):